No Data
Leap and Siro Unite to Unlock Total Sales Transparency With New Integration in SalesPro
Express News | Leap Therapeutics Announces Completion of Enrollment in Part B of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients
Leap LLC Secures Spot on the Inc. 5000 Fastest-Growing Companies List for the Fourth Consecutive Year
Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9
Baird analyst Joel Beatty maintains $Leap Therapeutics(LPTX.US)$ with a buy rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 47.6% and a
Leap Therapeutics Price Target Maintained With a $5.50/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5
H.C. Wainwright analyst Swayampakula Ramakanth maintains $Leap Therapeutics(LPTX.US)$ with a buy rating, and maintains the target price at $5.5.According to TipRanks data, the analyst has a success